Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 20;10(1):8368.
doi: 10.1038/s41598-020-65272-x.

Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas

Affiliations

Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas

Amal Mosaab et al. Sci Rep. .

Abstract

Pediatric high-grade gliomas (HGG) are rare aggressive tumors that present a prognostic and therapeutic challenge. Diffuse midline glioma, H3K27M-mutant is a new entity introduced to HGG in the latest WHO classification. In this study we evaluated the presence of H3K27M mutation in 105 tumor samples histologically classified into low-grade gliomas (LGG) (n = 45), and HGG (n = 60). Samples were screened for the mutation in histone H3.3 and H3.1 variants to examine its prevalence, prognostic impact, and assess its potential clinical value in limited resource settings. H3K27M mutation was detected in 28 of 105 (26.7%) samples, and its distribution was significantly associated with midline locations (p-value < 0.0001) and HGG (p-value = 0.003). Overall and event- free survival (OS and EFS, respectively) of patients with mutant tumors did not differ significantly, neither according to histologic grade (OS p-value = 0.736, EFS p-value = 0.75) nor across anatomical sites (OS p-value = 0.068, EFS p-value = 0.153). Detection of H3K27M mutation in pediatric gliomas provides more precise risk stratification compared to traditional histopathological techniques. Hence, mutation detection should be pursued in all pediatric gliomas. Meanwhile, focusing on midline LGG can be an alternative in lower-middle-income countries to maximally optimize patients' treatment options.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Cases and mutation distribution among the study cohort (a) Algorithm showing number of cases among different anatomical and histological subgroups (b) H3K27M mutation distribution among different anatomical and histological subgroups.
Figure 2
Figure 2
OS and EFS for different subgroups. (a) OS for mutant GII vs. GIII vs. GIV patients (b) EFS for mutant GII vs. GIII vs. GIV patients (c) OS for mutant FBSG vs. DIPG vs. thalamic gliomas (d) EFS for mutant FBSG vs. DIPG vs. thalamic gliomas (e) OS for diffuse mutant MLG vs. wild-type HGG (f) EFS for diffuse mutant MLG vs. wild-type HGG.

References

    1. Facts, C. Joinpoint Trends in Cancer Incidence Rates for Selected Sites in Two Age Groups, US, 1995–2015 35 Figure S6. Trends in Cancer Death Rates for Selected Sites. (2019).
    1. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: A review of 6212 cases from the surveillance, epidemiology, and end results database. Cancer. 2009;115:5761–5770. doi: 10.1002/cncr.24663. - DOI - PMC - PubMed
    1. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. doi: 10.1007/s00401-007-0243-4. - DOI - PMC - PubMed
    1. Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: Current concepts on diagnosis, biology, and clinical management. J. Clin. Oncol. 2017;35:2370–2377. doi: 10.1200/JCO.2017.73.0242. - DOI - PubMed
    1. Figarella-Branger D, et al. Les tumeurs gliales et glioneuronales de l’adulte et de l’enfant: principales altérations génétiques et classification histomoléculaire. Bull. Cancer. 2013;100:715–726. doi: 10.1684/bdc.2013.1789. - DOI - PubMed

Publication types

MeSH terms